Targeting CAF‐associated pathways, M2 macrophages, and TNF‐⍺ signaling could be novel therapeutic strategies for CMS4 PM‐CRC, as they might alter the tumor immune interplay and improve immunotherapy response. Here, TNF is linked to neoplasm.